
US drugmaker Eli Lilly (NYSE: LLY) has pulled out of the partnership with Transition Therapeutics (TSX: TTH) to develop its …
Transition Therapeutics is to abandon trials of its new diabetes treatment TT-223 following disappointing trial results. The Canadian biopharma company …

The Niagara Falls are one of the wonders of the natural world, and every year millions of visitors from around …
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact

